Navigation Links
Systematic Review of Patient-Reported Outcomes (PROs) Can Reduce Cost of Cancer Care
Date:4/28/2008

Supportive Oncology Services, Inc. leads PRO collection in community

oncology

MEMPHIS, Tenn., April 28 /PRNewswire/ -- Supportive Oncology Services (SOS), Inc. a research-based health-outcomes company specializing in oncology, issued the following statement today regarding the impact of Patient-Reported Outcomes (PROs) in the cancer community.

"Appropriate use of PRO information in the community oncology setting and timely intervention can significantly reduce the cost of patient care," according to Steve Coplon, CEO. "Avoidance of hospitalization dramatically reduces costs to treat cancer and improve health outcomes. For example, in our area an acute case requiring hospitalization for febrile neutropenia costs approximately $28,000 per event; hospitalization for anemia costs $23,000 per event; and hospitalization for severe nausea/vomiting costs $13,000 per event."

Dr. Kurt Tauer, Senior Partner with The West Clinic-Memphis states, "Conservatively, we keep over 75 patients per week out of the hospital and emergency room. Many of these avoided admissions are a direct result of patient self-reported assessments we collect via the PACE System(TM) e/Tablet. This crucial information enables our physicians to make appropriate interventions. We hear similar results from other community-based cancer clinics across the country."

The value of PROs in caring for the patient and potentially predicting and avoiding negative outcomes has been recently recognized by the Institute of Medicine (Cancer Care for the Whole Patient, 2008) and research published in the Journal of Clinical Oncology (J Clin Oncol 26:1355-1363). Additionally, Duke University's Cancer Program recognized the importance of PROs and implemented The PACE System(TM) in research projects across its Oncology Supportive Care department.

In April 2008, SOS announced it had accrued over one million cancer patient self-reported assessments using the PACE(TM) electronic e/Tablet system. Aggregated data from these self-assessments provides a rich resource for oncology research.

"All formal studies of the PACE(TM) System have proven that a more thorough and frequent assessment of the patient occurs when PROs are gathered by e/Tablets," affirms Edward J. Stepanski, PhD, Chief Operating Officer for SOS. "There is increasing recognition that PROs are the most accurate measure of symptoms and side effects. Thus, when clinicians routinely gather more, higher quality data and take action, good things happen for the patient."

For additional information contact Liz Conway, Director of Marketing and Corporate Services, 901-259-0878 or visit http://www.SupportiveOncologyServices.com.

About Supportive Oncology Services, Inc. (SOS)

Supportive Oncology Services, Inc. (SOS), an information and outcomes company, works closely with community oncology practices and oncology academic centers which provide treatment for over a half million cancer patients across the US. SOS also collaborates with bio-technology and pharmaceutical companies, the financial industry, payers, and other cancer-related industry leaders on diverse clinical, financial, and operational initiatives. By continuously offering improvements, measuring results and providing value, SOS helps define and improve the quality of cancer care provided.

Liz Conway

901-435-5570

Cell: 901-486-4872

lconway@sosacorn.com

Deborah D. Coble

901-683-0055 x1312

Cell: 901-831-1010

dcoble@sosacorn.com


'/>"/>
SOURCE Supportive Oncology Services, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The Diabetes Educator publishes systematic reviews for diabetes management
2. Methadone and systematic follow-up: the best solution for managing chronic pain
3. SEIU RN Dian Palmer Calls on AFL-CIO Head John Sweeney to Review Video From Dearborn Protest, Retract Statement Accepting CNA Distortions
4. Review Urges Aggressive MRSA Screening for Health Workers
5. ACC Calls on FDA to Update Review of Bisphenol A
6. Press Preview to Unveil Miracle Manny
7. PreMD Provides Update on FDA Review
8. Neuroscience Peer Review Consortium announces increased journal participation
9. ExoSeal vascular plug gets good reviews in ECLIPSE study
10. Symmetry Medical Delays 10-K Filing to Complete Review
11. Review of group-based cancer trials reveals flaws in studies design and analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... Frederick, Maryland (PRWEB) , ... June 24, 2016 ... ... Mid-Atlantic Angels is actively feeding the Frederick area economy by obtaining investment capital ... support over the past 2½ years that have already resulted in more than ...
(Date:6/24/2016)... ... 2016 , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The ... members that have been wounded in battle and their families. Venture Construction Group is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery ... Arizona pageant as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic ... , Dr. Olson says the decision to support the pageant in an ...
(Date:6/24/2016)... ... June 24, 2016 , ... To succeed under value-based ... however, are unsure how to move forward, given the need to sustain current ... forward tailored to an organization’s specific needs. , PYA Principal Martie Ross states, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: